NasdaqGS:CGONBiotechs
What CG Oncology (CGON)'s Royalty Lawsuit Win Means for Shareholders
In July 2025, CG Oncology announced that a Delaware jury unanimously ruled in its favor in a lawsuit brought by ANI Pharmaceuticals over royalties related to its investigational bladder cancer therapy, cretostimogene grenadenorepvec.
This outcome means CG Oncology is no longer required to pay any future royalties or damages to ANI Pharmaceuticals, eliminating a financial overhang tied to its lead therapeutic candidate.
We’ll explore how the company’s removal of future royalty obligations...